ADMA

ADMA Biologics, Inc. (NASDAQ:ADMA) is a biopharmaceutical company founded in 2004 and headquartered in Ramsey, New Jersey. The company went public in 2013 and has evolved from a development-stage biotechnology firm into a profitable manufacturer of specialty plasma-derived biologics. ADMA operates as the last remaining 100% U.S.-domiciled plasma therapeutics company, maintaining a vertically integrated supply chain from plasma collection through manufacturing and distribution. The company has transformed significantly over the past few years, achieving profitability and substantial revenue growth driven primarily by its flagship product ASCENIV.